Dec 05,2019

Philips and Paige Team Up to Bring Artificial Intelligence (AI) to Clinical Pathology Diagnostics

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Paige, a leader in computational pathology, announced a strategic collaboration to deliver clinical-grade AI applications to pathology laboratories. These AI technologies, starting with Paige Prostate, aim to help pathologists identify, quantify and characterize cancer in tissue samples and make precise diagnoses more efficiently. This may, ultimately, positively impact pathologist's workflow and treatment planning for patients.

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

View Analyst & Ambassador Comments
Go to original news
Dec 18,2019

Paige raises $45M more to map the pathology of cancer using AI

One of the more notable startups using artificial intelligence to understand and fight cancer has raised $45 million more in funding to continue building out its operations and inch closer to commercialising its work. Paige — which applies AI-based methods such as machine learning to better map the pathology of cancer, an essential component of understanding the origins and progress of a disease with seemingly infinite mutations (its name is an acronym of Pathology AI Guidance Engine) — says it will be use the funding to inch closer to FDA approvals for products it is developing in areas such as biomarkers and prognostic capabilities.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Dec 18,2019

Voluntis announces new pharma collaboration in oncology

Voluntis, a leader in digital therapeutics, announced today a collaboration with Novartis to evaluate the use of Voluntis’ digital therapeutic platform for Breast Cancer patients with the goal to empower patients with tools to more effectively manage symptoms and, thereby, improve patient experience and outcomes. This collaboration will leverage Voluntis’ Theraxium Oncology, the company’s core platform for digital therapeutics in the field of oncology.

COLLABORATION PARTNERSHIP

#r&d

#dtx

View Analyst & Ambassador Comments
Go to original news
Dec 27,2019

Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Xyphos Biosciences, Inc. (CEO: James Knighton, “Xyphos”) today announced that Astellas has acquired Xyphos. With the acquisition Astellas will gain Xyphos’ novel and proprietary ACCEL (Advanced Cellular Control through Engineered Ligands) technology platform, as well as industry-leading immuno-oncology talent, to develop new and potentially better ways to mobilize, target and control immune cells to find, modulate and destroy targeted cells throughout the body.

COLLABORATION MERGERS & ACQUISITION

#data & technology

#platform

View Analyst & Ambassador Comments
Go to original news
Dec 31,2019

Israeli algorithm may predict if cancer patients will respond to treatment

Only between 20% and 40% of cancer patients respond to immunotherapy treatments, according to the latest research published in the medical journal Cell. Now, an Israeli company says it has developed a method to analyze and predict individual patient responsiveness to therapy and discover new targets to overcome resistance, which could save money on treatment costs and, most importantly, improve patient outcomes.

PRODUCT

#platform

View Analyst & Ambassador Comments
Go to original news
Nov 15,2018

Does Teledermoscopy Improve The Efficacy Of Teledermatology?

Teledermatology refers to the practice of dermatology online without the initial need to see a physician in person. This industry, with a record expansion of more than 600% in recent times, is expected to be worth $7 billion by 2020. The power of connectivity offered by these systems supports the readiness of interaction between patients and doctors and provide a great platform to add teledermoscopy services to their practice. This article will discuss the benefits of implementing teledermoscopy in general dermatology for improved patient and doctor experience.

PRODUCT

#telehealth

#connected device

View Analyst & Ambassador Comments
Go to original news
Nov 02,2018

How Can Mobile Dermoscopy Support Practice Workflows?

Dermoscopy is an integral part of any dermatology practice. Shown to increase diagnostic accuracy of skin cancer and other conditions by as much as 35%, this tool represents some of the most innovative solutions introduced to the dermatology industry. Discover the top three ways mobile dermoscopes in particular are shown to streamline professional workflows for maximized efficiency.

PRODUCT

#connected device

View Analyst & Ambassador Comments
Go to original news
Nov 28,2018

Mobile Dermoscopy For The Early Detection of Melanoma & Other Skin Cancers

Skin cancer is a problem that affects us all, with one in seven Canadians developing a form of the condition within their lifetime. In spite of the widely recognized importance of prevention and early detection, the rates of melanoma continue to increase. Overwhelmed with cases while facing a profession shortage, dermatologists are struggling to keep up with the race against time because skin cancer doesn’t wait. Mobile dermoscopy for self imaging could help many in need of early detection.

#connected device

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 14,2018

How Are Digital Health Technologies Changing The Dynamics Of Human Relationships?

Within digital healthcare are millions of intricate pieces that comprise what is today’s care system. One of the core pieces of this elaborate scheme are human relationships: patients interacting with their physicians, doctors with their colleagues, and (perhaps the most ambiguous) medical professionals with health technologies. This article looks to summarize the changes that digital health tech has brought to these three primary areas of professional relationships with a focus on the dermatology and skin cancer industry.

#telehealth

#connected device

#ai/software

View Analyst & Ambassador Comments
Go to original news
Nov 20,2018

Skin Cancer Action Week: Empowering Patients & Doctors

Today marks day three of National Skin Cancer Action Week in Australia (held from Nov. 24th-28th). With 2 in 3 Australians diagnosed with skin cancer in their lifetime, this is an important opportunity to educate people about the importance of both prevention and early detection. Unfortunately, due to limited educational resources and professional personnel respectively, patients are often delayed from receiving the potentially life-saving care they require. These challenges can be comprised into three interconnected categories.

#ai/software

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY